Etrasimod
Etrasimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sphingosine 1-phosphate receptor 1. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 5.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 5 | 4 | — | — | 9 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | 1 | — | — | 2 |
Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | — | — | 1 |
Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | — | — | — | 1 |
Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | — | — | — | 1 |
Biliary liver cirrhosis | D008105 | K74.3 | — | 1 | — | — | — | 1 | |
Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | 1 | |
Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ETRASIMOD |
INN | etrasimod |
Description | Etrasimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sphingosine 1-phosphate receptor 1. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 5. |
Classification | Small molecule |
Drug class | immunomodulators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21 |
Identifiers
PDB | — |
CAS-ID | 1206123-37-6 |
RxCUI | — |
ChEMBL ID | CHEMBL3358920 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 6WH8495MMH (ChemIDplus, GSRS) |
Target
Agency Approved
S1PR1
S1PR1
Organism
Homo sapiens
Gene name
S1PR1
Gene synonyms
CHEDG1, EDG1
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 1
Protein synonyms
CD363, Endothelial differentiation G-protein coupled receptor 1, endothelial differentiation, sphingolipid G-protein-coupled receptor, 1, S1P receptor 1, S1P receptor Edg-1, Sphingosine 1-phosphate receptor Edg-1, sphingosine 1-phosphate receptor EDG1
Uniprot ID
Mouse ortholog
S1pr1 (13609)
sphingosine 1-phosphate receptor 1 (Q9R235)
Alternate
S1PR4
S1PR4
S1PR5
S1PR5
Organism
Homo sapiens
Gene name
S1PR4
Gene synonyms
EDG6
NCBI Gene ID
Protein name
sphingosine 1-phosphate receptor 4
Protein synonyms
Endothelial differentiation G-protein coupled receptor 6, endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 6, S1P receptor 4, S1P receptor Edg-6, Sphingosine 1-phosphate receptor Edg-6
Uniprot ID
Mouse ortholog
S1pr4 (13611)
sphingosine 1-phosphate receptor 4 (Q9Z0L1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 141 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more